How to Read Peptide Research Evidence

Not all published research carries the same weight. A randomized, placebo-controlled trial in people answers a very different question from a study in rats or in cells grown in a dish. For most research peptides the literature is mostly preclinical, so knowing which kind of study you are reading is the single most important step in interpreting it.

This guide explains the main study types, how we label them on product pages, and the evidence levels we assign to each compound.

Cell (in-vitro) studies expose cultured cells or tissue to a compound. They are fast and good for exploring mechanism, but a dish lacks absorption, metabolism, immune responses and the rest of a living organism.

Animal studies test a compound in living organisms, usually rodents. They show whole-body effects, but species differ in physiology and dosing, and many animal studies are small.

Human studies range from small open-label reports to large randomized controlled trials. Only well-designed controlled trials can establish whether an effect in people is real, and trials run for drug approval follow the phased process described in FDA development stages explained and on the FDA's page on the drug development process.

Reviews summarize other studies. A systematic review with defined search methods is stronger than a narrative review written by a compound's originating group.

Registered human trials, including ones that have not yet published results, can be looked up on ClinicalTrials.gov, the NIH registry.

Promising results in animals frequently fail in people. A review of highly cited animal research published in JAMA (Hackam and Redelmeier, 2006) found that fewer than half of those studies were later replicated in human randomized trials. Small sample sizes, flexible analyses and selective publication all inflate early findings, a problem set out in Ioannidis (PLoS Medicine, 2005) and in the Lancet series on research waste (Macleod et al., 2014).

So a sentence like “BPC-157 promoted tendon healing” means something specific: an effect was reported in a particular rat or cell model. It does not establish that the same thing happens, or is safe, in people.

Every cited study on a product page carries a label read from its design: Human study, Preclinical: animal, Preclinical: cell / in-vitro, or Review. Chemistry, analytical-method and background papers are left unlabelled.

Each compound also has an overall evidence level. Established (for the approved drug): the molecule is in an FDA-approved drug, so controlled human data exist for that regulated product, but not for research-grade material. Emerging: Phase 2 or 3 human trials exist but the molecule is not approved. Early human data: only Phase 1 safety and pharmacokinetic studies. Limited human evidence: no FDA program and only a few human reports. Preclinical / insufficient: cell and animal work only.

These labels describe the state of the literature, not the product in your vial, and none of them is a claim of safety or efficacy. Our testing and documentation page explains how we source and label research, and every product is sold strictly for research use only.

Ask four questions. Who or what was studied: cells, animals or people? How many: a handful of animals or hundreds of participants? Was there a control group, and was it randomized and blinded? Has it been replicated by an independent group? A claim that fails these questions is a hypothesis, not a finding.

Our comparison guides apply this approach to specific compounds: BPC-157 vs TB-500, retatrutide vs tirzepatide vs semaglutide, CJC-1295 vs ipamorelin vs sermorelin and Semax vs Selank.